XOMA Announces Positive Results from its Phase 2 Proof-Of … – Yahoo Finance
Posted: April 24, 2017 at 2:43 pm
BERKELEY, Calif., April 24, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (XOMA), a pioneer in the discovery and development of therapeutic antibodies, today announced that it has achieved positive Phase 2 proof-of-concept results for X213 in physiological hyperprolactinemia (HPRL). X213 is a monoclonal antibody that neutralizes prolactin action.
This proof-of-concept study was an important milestone in demonstrating the potential efficacy of this novel antibody. We believe that X213 could be a treatment option for a wide range of patients with hyperprolactinemia including prolactinoma and anti-psychotic induced HPRL as the signs and symptoms are similar irrespective of the etiology, said Jim Neal, Chief Executive Officer of XOMA. Consistent with our business strategy, we intend to maximize the value of X213 for shareholders by seeking a license partner for the program.
The Phase 2 study was a multi-center, open-labelled, randomized, single-dose, controlled trial of intravenously administered X213 in women who wished to suppress lactation immediately post-partum. The results of the study indicate that X213, when given as a single 700mg intravenous infusion during the first day post-partum, was effective in suppressing milk secretion, as well as breast engorgement and pain in 100 percent of the treated women. In addition, none of the treated women experienced rebound breast symptomatology during the 21-day study period. While the study was not intended, or powered to show statistical significance, it demonstrated that X213 was: safe and well tolerated; caused no significant adverse events (SAEs); showed favorable pharmacokinetics with a terminal half-life of two weeks and; demonstrated target (prolactin receptor) engagement and mechanism of action confirmation by serum prolactin profiling.
The findings from this proof-of-concept study are encouraging and confirm that X213 inhibits prolactin signaling and thus, may be effective in blocking effects of symptomatic hyperprolactinemia, said Dr. Shlomo Melmed, endocrinologist, Dean of the Medical Faculty and Professor of Medicine, Cedars-Sinai Medical Center, Los Angeles. New classes of drugs such as X213 may offer benefit to the up to 20 percent of patients who do not respond to, or are intolerant of, current standard of care involving dopamine agonist medications.
Prolactin is a multifunctional hormone that is primarily secreted by the pituitary and whose best-known functions are related to lactation and reproduction. In pregnant women, excess prolactin secretion (hyperprolactinemia) occurs to enhance breast development and to induce lactation postpartum. Commonly encountered etiologies of hyperprolactinemia include prolactinoma, medication effect, kidney failure, cystic or granulomatous pituitary lesions, and disorders which interfere with hypothalamic inhibition of prolactin release. Prolactinomas, benign tumors of the pituitary gland, hypersecrete prolactin with significant medical consequences, particularly hypogonadism, infertility and osteoporosis.
About X213 X213 (formerly LFA 102) is a first-in-class allosteric inhibitor of prolactin action. It is a humanized IgG1-Kappa monoclonal antibody that binds to the extracellular domain of the human prolactin receptor with high affinity at an allosteric site. The antibody has been shown to inhibit prolactin-mediated signaling, and it is potent and similarly active against animal and human prolactin receptors.
The Phase 2 study evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of X213 in post-partum women. The study was conducted at multiple medical centers in Spain.
About XOMA Corporation XOMA has an extensive portfolio of products, programs, and technologies that are the subject of licenses the Company has in place with other biotech and pharmaceutical companies. Many of these licenses are the result of the Company's pioneering efforts in the discovery and development of antibody therapeutics. There are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. In order to maximize its value in a licensing transaction, XOMA continues to invest in X358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. For more information, visit http://www.xoma.com.
Read More
Forward-Looking Statements Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding: X213 as a potential treatment option for patients with hyperprolactinemia including prolactinoma and anti-psychotic induced HPRL; XOMA's portfolio of partnered programs and licensed technologies; XOMA's intent to license X213 and X358; and statements that otherwise relate to future periods. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. Potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-K and in other SEC filings. Consider such risks carefully when considering XOMA's prospects. Any forward-looking statement in this press release represents XOMA's views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law.
Continued here:
XOMA Announces Positive Results from its Phase 2 Proof-Of ... - Yahoo Finance
- Testosterone Treatment and Fractures in Men with Hypogonadism | NEJM - nejm.org - January 20th, 2024
- Understanding Hypogonadism, Testosterone Replacement Therapy, and Prostate Cancer Risk - Medriva - January 11th, 2024
- Male hypogonadism - Patient Information - January 3rd, 2024
- Testosterone replacement therapy may not increase risk of prostate cancer among men with hypogonadism - Medical Dialogues - January 3rd, 2024
- Male Hypogonadism Market Expected to Reach $5.1 Billion by 2030 | Current Trends and Industry Analysis - EIN News - December 16th, 2023
- Hypogonadism: What Is It, Causes, Signs and Symptoms, and More - Osmosis - November 2nd, 2023
- Hypogonadism - StatPearls - NCBI Bookshelf - February 10th, 2023
- Male hypogonadism: Symptoms and treatment - PMC - PubMed Central (PMC) - February 10th, 2023
- The 'male menopause' - NHS - November 26th, 2022
- Diagnosis of Hypogonadism: Clinical Assessments and Laboratory Tests - November 1st, 2022
- Approach to the Patient With Hypogonadotropic Hypogonadism - November 1st, 2022
- Clomiphene citrate for men with hypogonadism: a systematic ... - PubMed - September 21st, 2022
- Hypogonadism in females | DermNet - September 21st, 2022
- Clomiphene citrate effects on testosterone/estrogen ratio in male ... - September 21st, 2022
- Male Hypogonadism Market Size to Grow by USD 684.95 Mn, AbbVie Inc. and Bayer AG Among Key Vendors - Technavio - Longview News-Journal - September 21st, 2022
- Male sexual health and reproductive medicine: All that glitters is not gold - Urology Times - September 21st, 2022
- The Reproductive Outcome of Women with HH in IVF - Physician's Weekly - August 20th, 2022
- Men's Health Market is Slated to Witness Tremendous Growth in Coming Years | Latest Report by IBI - Digital Journal - August 20th, 2022
- Why Can Some Medicines Increase The Risk Of Osteoporosis? - Nation World News - August 20th, 2022
- What is Erectile dysfunction (aka ED)? : Buy Kamagra to treat the ED - My MMA News.com - August 20th, 2022
- Sure Signs Your Endocrine System Isn't as Strong as it Should Be Eat This Not That - Eat This, Not That - August 11th, 2022
- What has the NFL said about Packers QB Rodgers consuming ayahuasca? - AS USA - August 11th, 2022
- Male hypogonadism: Symptoms, causes, and treatment - Medical News Today - July 8th, 2022
- Hypogonadism in Men | Endocrine Society - July 8th, 2022
- Olfactory Radioanatomical Findings in Patients With Cardiac Arrhythmias, COVID-19, and Healthy Controls - Cureus - July 8th, 2022
- Global Hormone Replacement Therapy Market Is Projected To Thriving At A CAGR of 1.51% During 2022-2028 | 120 Report Pages - Digital Journal - July 8th, 2022
- Testosterone May Aid Memory in Men With Uncontrolled Diabetes - Everyday Health - June 28th, 2022
- Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer Patients: A Systematic Review - Cureus - June 28th, 2022
- EffRx Pharmaceuticals Signs Exclusive License Agreement With Diurnal for the Registration and Commercialization of Efmody in Switzerland - Business... - April 28th, 2022
- Tucker Carlson hawks testicle tanning to boost testosterone. Experts say it may do the opposite - Salon - April 28th, 2022
- A practical guide to male hypogonadism in the primary care ... - January 1st, 2022
- Waist Circumference Is More Closely Associated with Hypogonadism than Is Hyperglycemia, Independent of BMI in Middle-Aged Men - DocWire News - January 1st, 2022
- Andrological aspects of new coronavirus infection Covid-19 - DocWire News - January 1st, 2022
- Reviewing the Top 5 Best Male Enhancement Pills in 2022 to Buy - The Daily World - January 1st, 2022
- Low Sex Drive (Hypogonadism): Symptoms, Treatment - December 22nd, 2021
- Androgen Deprivation Therapy and the Risk for Inguinal Hernia: An Observational Nested Case Control Study - DocWire News - December 22nd, 2021
- 5 Best Testosterone Boosters to Increase Testosterone Levels in 2022 - Us Weekly - December 22nd, 2021
- Male hypogonadism | You and Your Hormones from the Society ... - November 21st, 2021
- Low testosterone predicts hypoxemic respiratory insufficiency and mortality in patients with COVID-19 disease: another piece in the COVID puzzle -... - November 21st, 2021
- CLARUS THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) -... - November 21st, 2021
- Bio-Identical Hormone Replacement Therapy Market to Rise Due to the Increasing Applications and Wider Reach, Players Pfizer Bayer. Energy Siren -... - November 21st, 2021
- Hormone Replacement Therapy Market Rise in Sustainability Around The World 2021 2030 - Taiwan News - October 5th, 2021
- 6 Things To Look for In a Good Testosterone Booster Supplement - The Portugal News - October 5th, 2021
- Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer - DocWire News - October 5th, 2021
- [PDF] Hormone Replacement Therapy Market to Reflect Steady Growth and Future Scope UNLV The Rebel Yell - UNLV The Rebel Yell - August 30th, 2021
- Top 6 Benefits of Testosterone Therapy Times Square Chronicles - Times Square Chronicles - August 3rd, 2021
- Hormone Replacement Therapy Market by 2027 Worldwide Growth Opportunities Recent Trends Forecast by Types and Application to 2027 The Manomet Current... - August 3rd, 2021
- 9 Ways to Increase Testosterone Naturally in 2021 - Men's Journal - August 3rd, 2021
- Testosterone Therapy for Hypogonadism Guideline Resources ... - May 26th, 2021
- Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory Breast Disease And... - May 26th, 2021
- Trending Report of Male Hypogonadism Market Drivers, Strategies, Applications and Competitive Landscape 2026 Brockville Observer - Brockville... - May 26th, 2021
- Male menopause: Here's everything you need to know about andropause - Pulse Ghana - May 26th, 2021
- Blue Water Acquisition : Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory... - May 26th, 2021
- Hormone Replacement Therapy Market Size to Surpass US$ 36.54 Billion by 2027 with the CAGR of 8.20% The Manomet Current - The Manomet Current - May 26th, 2021
- The many effects of reproductive hormones on the brain - ESHRE - May 26th, 2021
- Hormone Replacement Therapy (HRT) Market to Eyewitness Stunning Growth by 2027 Covid-19 Analysis The Shotcaller - The Shotcaller - May 26th, 2021
- The Male Hypogonadism Market To Witness Steadfast Growth In The Next 10 Years The Courier - The Courier - May 14th, 2021
- The Male Hypogonadism Market To Ride On Innovations KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper - May 14th, 2021
- Hormone Replacement Therapy Market Global Industry Scope and Growth Analysis Report 2021: Opportunity Assessment, Business Boosting Strategies, and... - May 14th, 2021
- Global Hormone Replacement Therapy (HRT) Industry Market Report 2020, Forecast Till 2027 By Type, End-use, Geography and Player The Courier - The... - May 14th, 2021
- Immunosenescence Profile and Expression of the Aging Biomarker (p16INK4a) in Testicular Cancer Survivors Tr... - UroToday - February 11th, 2021
- Europe to hold The major Piece of Cake in the Anabolic Steroids Market between 2020 and 2030 Jumbo News - Jumbo News - February 11th, 2021
- The Male Hypogonadism Market to witness a splendid CAGR in the next decade Murphy's Hockey Law - Murphy's Hockey Law - February 3rd, 2021
- Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Pha... - UroToday - February 3rd, 2021
- Marius Pharmaceuticals Announces Co-CEOs Himanshu H. Shah and Shalin Shah to Drive Growth ahead of Anticipated FDA Action of its Lead Asset, KYZATREX... - January 29th, 2021
- Male Hormone Replacement Therapy And The Side Effects - Nerd's Magazine - January 29th, 2021
- New York Medical and Life Sciences: Year in Review 2020 - JD Supra - January 29th, 2021
- Male menopause: symptoms, diagnosis and treatment - Netdoctor - January 29th, 2021
- Freeman: 'Pressure to Succeed' Led to Testosterone Order - Medscape - January 27th, 2021
- Hormone Replacement Therapy Market Growth Analysis,Size,Insight,Share And Outlook By 2027 Pfizer, AbbVie, Novo Nordisk NeighborWebSJ - NeighborWebSJ - January 27th, 2021
- Male Hypogonadism Therapy Market to Witness Massive Growth During 2021-2027 | Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva,... - January 25th, 2021
- Male Hypogonadism Therapy Market and Ecosystem by Production, Prospects, Consumption, Cost Structure, Competitive Landscape - Jumbo News - January 25th, 2021
- What is Harvey Prices disability Prader-Willi Syndrome? - The Sun - January 25th, 2021
- The Male Hypogonadism Market To Witness An Escalating CAGR Of 3.7% - NeighborWebSJ - January 19th, 2021
- Androgen Replacement Therapy Market to Witness Robust Expansion throughout the Forecast Period 2017-2026 | AbbVie, Inc., Allergan Plc, Bayer AG, Endo... - January 19th, 2021
- Global COVID-19 Diagnostics Market Size Worth USD 11.40 Billion at 7.9% CAGR; Pharmaceutical Giants Such as Abbott and Roche to Pump More Funds for... - January 19th, 2021
- Marius Pharmaceuticals Submits New Drug Application to US FDA for Next-Generation Oral Testosterone Replacement Therapy in Male Patients With... - January 12th, 2021
- Testosterone Replacement Therapy Market (2020 2027) Explosive Factors of Revenue by Key Manufacturer, Share, Future Trends, COVID-19 Market Scenario,... - January 9th, 2021
- The Anabolic Steroids Market to sharpen in the next decade - The Monitor - January 9th, 2021
- Brief Report Treatment of infertility and menopause in a patient with multiple sclerosis affecting the pituitary stalk: a case report - DocWire News - December 24th, 2020